NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Nyxoah and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Nyxoah and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Nyxoah and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Nyxoah and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, April 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Nyxoah and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

LOS ANGELES, April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or "the Company") (NASDAQ: NYXH) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nyxoah issues a press release on March 25, 2025, "announcing that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA) application for the Genio® system", adding that the letter "means that Nyxoah's application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA's PMA implementing regulations … and the FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review." Analyst noted that the Company's announcement will likely result in a delay in Genio's commercial launch. Based on this news, shares of Nyxoah fell by more than 21.3% on the next day.

NEW YORK, March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Nyxoah and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.